Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 09/28 | 09/30 | 4,126 sh | $57.88 | $238,812.88 | −50.0% |
EVP & Chairman, Partnering | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 09/22 | 09/24 | 100,000 sh2 trades | $58.53avg. | $5,853,095.17 | −27.0% |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 06/24 | 06/25 | 9,098 sh | $55.18 | $502,027.64 | −50.0% |
EVP & Chairman, Partnering | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 06/23 | 06/25 | 150,000 sh2 trades | $54.39avg. | $8,158,833.12 | −21.1% |
Terrance P. CoyneEVP & CFO | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 05/26 | 05/28 | 64,399 sh | $53.98 | $3,476,258.02 | −100.0% |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 05/20 | 05/21 | 13,684 sh | $52.75 | $721,831 | −42.9% |
Gregory NordenDirector | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 05/14 | 05/15 | 3,045 sh | $53.00 | $161,385 | −1.6% |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 05/14 | 05/15 | 13,684 sh | $53.06 | $726,073.04 | −30.0% |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 04/28 | 04/30 | 34,791 sh2 trades | $49.78avg. | $1,731,895.98 | −46.4% | |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 04/01 | 04/02 | 34,791 sh2 trades | $48.33avg. | $1,681,449.03 | −51.4% | |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 03/23 | 03/25 | 34,791 sh2 trades | $45.53avg. | $1,584,034.23 | −44.2% | |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 03/02 | 03/04 | 34,791 sh4 trades | $46.78avg. | $1,627,440.05 | −43.2% | |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 02/23 | 02/25 | 34,791 sh2 trades | $45.32avg. | $1,576,728.12 | −42.2% | |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 02/02–02/04 | 02/04 | 243,541 sh6 trades | $42.54avg. | $10,359,967.55 | −91.4% | |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/30 | 02/02 | 20,000 sh | $41.09 | $821,800 | −100.0% |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/23 | 01/26 | 20,000 sh | $40.26 | $805,200 | −50.0% |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/20 | 01/23 | 69,582 sh2 trades | $39.35avg. | $2,738,051.7 | −65.9% | |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/16 | 01/20 | 20,000 sh | $39.52 | $790,400 | −33.3% |
Marshall UristEVP, Research & Investments | Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/09 | 01/13 | 20,000 sh | $40.78 | $815,600 | −25.0% |
Royalty PharmaRPRX | Open-market sale10b5-1 plan | 01/02 | 01/06 | 69,582 sh2 trades | $38.42avg. | $2,673,340.44 | −63.6% |
